GRFS is trading at $7.50 (+5.9%) after-hours following news that the company dosed the first patient in its SWIFT-SC Phase 3 trial for a self-administered alpha-1 antitrypsin deficiency treatment.
- The clinical milestone involves a higher-concentration Alpha1-Proteinase Inhibitor, which aims to provide a more convenient, self-administered option for patients.
- The after-hours move marks a rebound from a weaker regular session close, as investors shift focus to pipeline progress despite broader valuation concerns in the plasma-therapeutics sector.